In late August, the FDA approved a genetic test that scores heart transplant patients post surgically for organ rejection.  By looking at the expression patterns of twenty genes in leukocytes, this “AlloMap” test, from XDx, Inc. (Brisbane, CA), can evaluate rejection potential without a heart biopsy. According to the American Heart Association, more than 2,000 heart transplants were done in the US during 2006 and 25% of patients have some sign of rejection at least once during their first year after surgery.  SEE THE ALLOMAP PAPER